HSG in the News!
Read the latest article:
"ARC-HD"
"First-HD"
Dr. Samuel Frank - Overview of First-HD
Stay Connected!
HSG Clinical Trials
sponsored by Teva
Pharmaceuticals.

LEGATO-HD is a Phase 2
Laquinimod HD Study and
is currently enrolling.

Pride-HD is a Phase 2
Pridopidine HD Study and
has completed enrollment.
SIGNAL is a Phase 2 research trial for people who are at risk for
Huntington Disease (HD) and have early signs of HD. The study will
assess the safety, tolerability, and effectiveness of VX15 (a novel
monoclonal antibody). To learn more or to start the enrollment
process, please contact the Huntington Study Group at
+1-800-487-7671 (Toll Free (North America) or
info@hsglimited.org.
Help 4 HD International is a proud communications partner of the
Huntington Study Group (HSG) since 2011 and plays a vital role in
connecting our HD community with clinical trial information and
education.  Our mission includes partnering with institutions, industry
and other nonprofit organizations to bridge the gap. The HSG is
made up of clinical researchers clinicians and care providers
worldwide for HD patients and families and who are working
diligently to combat this disease. New research trials for HD are
currently enrolling, so be sure to contact them directly.  We ask you to
visit our website for monthly updates and greatly appreciate your time
and effort in seeking treatments that make a difference for Huntington
disease. Please visit the links below to learn about the different
studies and trials going on now!  Join the HSG
Facebook page!

For additional information please contact:
Liz McCarthy:
info@hsglimited.org
Tel: 800-487-7671 (toll-free in North America)
www.HSGLimited.org
A Proud Partner of the HSG
Highlighting HSG on Help4HD!
Radio
1
LEGATO-HD
Dr. Andrew Feigin & Dr. Karen Elta
Anderson
Help4HD
2
SIGNAL
Dr. Andrey Feigin
Help4HD
3
News Update
FIRST-HD
ARC-HD
Samuel Frank, MD - PI
Claudia Testa, MD, PhD - Co-PI
David Stamler, MD - CMO Auspex
Pharmaceuticals
Sarah Janicki, MD, MPH – Site
Investigator, Columbia for First-HD
Help4HD
4
CREST-E
Update with Bonnie Hennig &
Karen Hodgeman
Help4HD
5
News Update
FIRST-HD
Samuel Frank, MD - PI
David Stamler, MD - CMO Auspex
Pharmaceuticals
Help4HD
6
News Update
Dr. Ira Shoulson
Help4HD
7
FIRST-HD
Samuel Frank, MD - PI
David Stamler, MD - CMO Auspex
Pharmaceuticals
Help4HD
8
PREQUEL
Dr. Christopher Ross
Help4HD
9
CREST-E
Dr. Diana Rosas
Help4HD
10
The HD View
Dr. Ira Shoulson
Help4HD
11
REACH2-HD
PBT2 / Prana
Help4HD
12
News Update
Help4HD - Dr. Ira Shoulson
Help4HD
13
News Update
REACH2-HD
Dr. Martha Nance, Steering
Commttee PREDICT-HD, ENROLL-HD
Dr. Sarah Janicki, Columbia U
Dr. Carlos Singer, U Miami
Ronda Clouse, RN, Columbia U
Amy Duffy, Study Coordinator/Mayo
Clinic
Help4HD
14
The HD View
Jody Goldstein Study Coordinator
Help4HD
15
News Update
REACH2-HD
Dr. Ray Dorsey, Johns Hopkins
University (PI)
Dr. Caroline Herd, Prana
Jody Goldstein
Help4HD
16
REACH2-HD
Dr. Ray Dorsey, Johns Hopkins
University (PI)
Diane Angus, COO, Prana
Help4HD
17
2CARE
Elisabeth (Lisa) de Blieck, MPA
CCRC
Help4HD
18
CREST-E
Dr. Diana Rosas, Mass General
(Co-PI)
Help4HD
19
PREDICT-HD
Anne Leserman, Recruitment
Coordinator, University Iowa
Pat Ryan, Research Coordinator, UI
Help4HD
20
2CARE
Dr. Merit Cudkowicz, Harvard (PI)
Help4HD
21
CREST-E
Giovanni Schifitto, MD, MS,
University Rochester, (PI)
Help4HD
22
CREST-E
Steven Hersch, MD, PhD, Mass
General & Harvard (PI) REVEAL-HD,
CREST-E
Help4HD
23
Help4HD Radio
Dr. Ira Shoulson, Georgetown
University
Help4HD
HSG
Barcode Maker
HSG EVENTS &
OTHER HD PICS